Search research articles
Contact Us
Filters
Showing results (61-70 of 78) with videos related to
Page
of 8
Sort By:
Cancer Communications (London, England)
|
June 28, 2023
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients
Anna Giuliano, Barbara Kuter, Shari Pilon-Thomas, et al.
Leukemia Research
|
December 21, 2022
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients
Somedeb Ball, Luis E Aguirre, Akriti G Jain, et al.
American Journal of Hematology
|
September 14, 2023
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia
Parth C Patel, Somedeb Ball, Akriti G Jain, et al.
American Journal of Hematology
|
February 18, 2022
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Somedeb Ball, Akriti G Jain, Luis E Aguirre, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 9, 2023
Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion
Yumeng Zhang, Lynn Nguyen, Chuanyi M Lu, et al.
JAMA Oncology
|
March 10, 2022
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida
Anna R Giuliano, Jeffrey E Lancet, Shari Pilon-Thomas, et al.
British Journal of Haematology
|
June 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, et al.
Cancer
|
September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations
Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
Blood Advances
|
January 3, 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML
Onyee Chan, Najla Al Ali, Hammad Tashkandi, et al.
American Journal of Hematology
|
August 7, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia
Somedeb Ball, Akriti G Jain, Najla Al Ali, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 78) with videos related to
Sort By:
Page
of 8
Cancer Communications (London, England)
|
June 28, 2023
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients
Anna Giuliano, Barbara Kuter, Shari Pilon-Thomas, et al.
Leukemia Research
|
December 21, 2022
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients
Somedeb Ball, Luis E Aguirre, Akriti G Jain, et al.
American Journal of Hematology
|
September 14, 2023
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia
Parth C Patel, Somedeb Ball, Akriti G Jain, et al.
American Journal of Hematology
|
February 18, 2022
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Somedeb Ball, Akriti G Jain, Luis E Aguirre, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 9, 2023
Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion
Yumeng Zhang, Lynn Nguyen, Chuanyi M Lu, et al.
JAMA Oncology
|
March 10, 2022
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida
Anna R Giuliano, Jeffrey E Lancet, Shari Pilon-Thomas, et al.
British Journal of Haematology
|
June 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, et al.
Cancer
|
September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations
Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
Blood Advances
|
January 3, 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML
Onyee Chan, Najla Al Ali, Hammad Tashkandi, et al.
American Journal of Hematology
|
August 7, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia
Somedeb Ball, Akriti G Jain, Najla Al Ali, et al.
Page
of 8